论文部分内容阅读
目的：瘤体注射重组腺病毒基因治疗Ｇ４２２小鼠胶质母细胞瘤皮下荷瘤模型，观察联合ＩＬ－２／ＩＬ－３基因治疗胶质瘤。方法： 瘤体注射腺病毒基因治疗后，观察肿瘤的大小，荷瘤小鼠的存活期，脾细胞的ＮＫ、ＬＡＫ、ＣＴＬ的杀伤活性，并常规病理分析肿瘤标本。结果：瘤体注射腺病毒ＩＬ－２、ＩＬ－３基因治疗Ｇ４２２皮下荷瘤模型后，肿瘤的生长受抑制，荷瘤小鼠的存活期延长，小鼠脾细胞的ＮＫ、ＬＡＫ、ＣＴＬ杀伤活性增强，肿瘤局部出现更多的肿瘤坏死和炎细胞浸润。结论：联合ＩＬ－２／ＩＬ－３基因治疗可以进一步增强治疗的效果。
OBJECTIVE: To study the effect of injecting recombinant adenovirus into G422 mice glioblastoma subcutaneous tumor model in combination with IL-2 / IL-3 gene therapy. Methods: The tumor size, the survival of tumor-bearing mice, NK, LAK and CTL cytotoxic activity of spleen cells were observed after tumor-injected adenovirus gene therapy, and routine pathological analysis of tumor samples. Results: The growth of tumor-bearing mice was prolonged after tumor cells were injected with adenovirus IL-2 and IL-3 gene in G422 subcutaneous tumor-bearing model. The NK, LAK and CTL cytotoxicity of mouse spleen cells were prolonged Enhanced tumor local tumor necrosis and inflammatory cell infiltration. Conclusions: The combination of IL-2 / IL-3 gene therapy can further enhance the therapeutic effect.